Investigating RELEARN Neurofeedback as Treatment for Chronic Musculoskeletal Pain
WithdrawnPhase 2, Phase 3NCT05335486
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
This clinical investigation will be carried out as a randomized controlled trial conducted at the Northern Regional Hospital, Hjørring. This investigation will enrol 36 patients suffering from severe knee osteoarthritis pain, primarily from the orthopaedic ward at Hjørring Hospital, where potential participants will be identified during routine consultations. The RELEARN intervention consists of encephalography (EEG) neurofeedback of cerebral movement evoked signatures of pain, where the participants will be instructed in attempting to manipulate these signatures to reduce pain perception. This investigation is carried out to analyse the clinical performance and safety of the RELEARN neurofeedback software.
Study details
- Official title
- Investigating RELEARN Neurofeedback as Treatment for Chronic Musculoskeletal Pain
- Interventions
- Device: RELEARN Neurofeedback
- Other: Standard care control
- Sponsor
- Redo-Neurosystems
- Collaborators
- Regionshospital Nordjylland
- Start date
- 2022-10-05
- Primary completion
- 2023-07-01
- Sex
- All
- Age range
- from 18 Years to 65 Years
- Results posted
- No results posted in this snapshot
- Countries
- Denmark
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: 1. Age 18-65 years old 2. Knee arthrosis (Kellgren-Lawrence score of ≥ 2) 3. 24h VAS ≥ 4 4. Ongoing pain, lasting more than three months Exclusion Criteria: Participants who meet any of the below criteria will be excluded from the investigation: 5. Pregnant or lactating woman 6. Use of opioids or cannabis 7. Active drug addiction defined as the use of cannabis, opioids, or other drugs 8. Previous or current neurologic, systemic, or mental illness, including any liver, kidney or metabolic disease. 9. Rheumatoid arthritis 10. Evidence of other pain types such as visceral, neuropathic, or malignant pain. 11. Evidence of other sources of ongoing pain such as root affect, traumas, or congenital malformation 12. Severe inflammation in the area of interest 13. Blindness or deafness 14. Consumption of alcohol, caffeine, nicotine on test day 15. Recent history of fractures or surgery in the area of interest 16. Participation in other clinical trials throughout the study period and one month prior to participation 17. History of epilepsy 18. Obesity class III and above. I.e. BMI \> 39,9
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT05335486